The filing was made under the accelerated approval pathway, the company said, adding the regulator has given breakthrough therapy designation to RP1 plus nivolumab in the same setting.

Replimune shares were rising nearly 19% in recent after-hours trading.

Price: 13.10, Change: +2.05, Percent Change: +18.55

http://www.mtnewswires.com
Copyright © 2024 MT Newswires. All rights reserved. MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.